IRCT20200416047099N1
Recruiting
未知
se of convalescent plasma in the treatment of patients with severe COVID-19 pneumonia
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 10
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria of plasma donor (1\-9\) Recovery from 2019\-nCoV infection according to clinical and laboratory criteria
- •Pass the at least 28 days after hospital discharge
- •Negative RT\-PCR test ( 2 times with 48 h interval)
- •Negative results of serum/plasma for HBV, HCV, HTLV, HIV, and Syphilis
- •ABO, and RH antigens determination
- •Fill informed consent to collect 650\-1300 apheresis
- •Inclusion criteria of recipient (11\-15\)
- •Confirmed the diagnosis of nCoV infection by RT\-PCR
- •Respiratory \> 30 beats/min
- •PaO2 / FiO2 \=300 mmHg
Exclusion Criteria
- •Exclusion criteria of plasma donor (2\-13\)
- •Active respiratory infection symptoms: cough, dyspnea, oxygen requirements during 3 days ago
- •History of Cardiac congestion, pulmonary hypertension, and other situation leading to apheresis failure
- •Bleeding history and anti\-coagulant agent therapy
- •HBV vaccination during last week Receiving live\-attenuated vaccines including BCG, yellow fever, measles, mumps, polio and typhoid fever during over the past three weeks
- •Receiving IVIG injection, anti\-tetanus, and other passive immunization over the past 6 weeks
- •Small pox vaccination or contact with a person who receive Small pox vaccine
- •Undefined loss weight \> 4\.5 kg, apheresis over the past three months
- •Diagnosis of Dengue fever, Induced abortion, and blood transfusion over the past 6 months
- •Exclusion criteria of recipient (11\-14\)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
se of plasma of cured person to treat patient with severe covid-19Coronavirus infection, transfusion, C23, A00-B99, Coronavirus OC43, Human.A00-B99RBR-7f4mt9fHemocentro de Ribeirão Preto
Recruiting
Phase 3
Convalescent Plasma Therapy from Recovered Patients to Treat COVID-19 Early in SARS-CoV-2 DiseaseNL-OMON49795Erasmus MC, Universitair Medisch Centrum Rotterdam690
Completed
Phase 3
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/06/025803Institute of Liver and Biliary Sciences400
Completed
Phase 2
Effect of convalescent plasma in COVID-19 patientsHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/04/024706Institute of Liver and Biliary Sciences29
Recruiting
Not Applicable
A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-ICU patients with COVID-19 infectionsCOVID-19NL-OMON23835eiden University Medical Center430